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Summary
Mutations in the Plasmodium falciparum chloroquine
(CQ) resistance transporter (PfCRT) are major deter-
minants of verapamil (VP)-reversible CQ resistance
(CQR). In the presence of mutant PfCRT, additional
genes contribute to the wide range of CQ suscepti-
bilities observed. It is not known if these genes influ-
ence mechanisms of chemosensitization by CQR
reversal agents. Using quantitative trait locus (QTL)
mapping of progeny clones from the HB3 ¥ Dd2
cross, we show that the P. falciparum multidrug resis-
tance gene 1 (pfmdr1) interacts with the South-East
Asia-derived mutant pfcrt haplotype to modulate CQR
levels. A novel chromosome 7 locus is predicted to
contribute with the pfcrt and pfmdr1 loci to influence
CQR levels. Chemoreversal via a wide range of
chemical structures operates through a direct pfcrt-
based mechanism. Direct inhibition of parasite
growth by these reversal agents is influenced by pfcrt
mutations and additional loci. Direct labelling of
purified recombinant PfMDR1 protein with a highly
specific photoaffinity CQ analogue, and lack of com-
petition for photolabelling by VP, supports our QTL
predictions. We find no evidence that pfmdr1 copy
number affects CQ response in the progeny; however,
inheritance patterns indicate that an allele-specific
interaction between pfmdr1 and pfcrt is part of the
complex genetic background of CQR.
Introduction
Efforts against Plasmodium falciparum are hampered by
the evolution and worldwide spread of decreasing para-
site susceptibility to an array of antimalarial compounds,
including the near global failure of the former mainstay
drug, chloroquine (CQ) (Ginsburg, 2005). Extensive field
and laboratory research on CQ resistance (CQR) iden-
tified the crucial role of a gene on chromosome (chr) 7,
the P. falciparum CQR transporter (pfcrt), that encodes a
putative transporter with channel-like properties, local-
ized to the digestive vacuole membrane in erythrocytic
stage parasites (Wellems et al., 1991; Su et al., 1997;
Fidock et al., 2000; Cooper et al., 2002; Sidhu et al.,
2002; Zhang et al., 2004; Martin et al., 2009; Paguio
et al., 2009). A K76T change is ubiquitous in
CQ-resistant populations and is a reliable molecular
marker of CQR (Djimde et al., 2001; Wootton et al.,
2002; Chen et al., 2003; Plowe, 2003; Best Plummer
et al., 2004; Durrand et al., 2004).
Drug pressure in the laboratory to select mutant
CQ-resistant parasite lines has been successful in only
one CQ-sensitive (CQS) parasite line, 106/1 (Fidock et al.,
2000; Cooper et al., 2002), which is unique in harbouring
six of the seven PfCRT mutations characteristic of South-
East Asian CQ-resistant parasites, lacking only the critical
K76T (Wootton et al., 2002). Attempts to select for CQR
using other CQS parasite lines have failed (Lim and
Cowman, 1996). In other experiments, the wild-type
PfCRT allele of GC03, a CQS progeny clone of the
HB3 ¥ Dd2 genetic cross with a haplotype of CMNKAQNIR
at amino acid positions 72, 74, 75, 76, 220, 271, 326, 356
and 371, was replaced with three unique CQ-resistant
haplotypes: CIETSESTI (Dd2), CIEISESII (106/176I) and
SMNTSQDLR (7G8) by homologous recombination
(Sidhu et al., 2002). Various allelic replacements confer
distinct CQR phenotypes in GC03 (Sidhu et al.,
Accepted 23 August, 2010. *For correspondence. E-mail ferdig.1@
nd.edu; Tel. (+1) 574 631 9973; Fax (+1) 574 631 7413. †Contributed
equally.
Molecular Microbiology (2010) 78(3), 770–787  doi:10.1111/j.1365-2958.2010.07366.x
First published online 28 September 2010
© 2010 Blackwell Publishing Ltd
2002; Lakshmanan et al., 2005). Collectively, these
studies underscore the major role of amino acid 76 in CQR,
but also indicate an important role for additional factors in
the genetic background of the key PfCRT mutation.
The suggestion that multiple genetic factors underpin
CQR was raised more than 20 years ago, well before the
identification of pfcrt (Foote et al., 1990). A strong but
incomplete association of mutations in pfmdr1, a gene
encoding a P-glycoprotein homologue (Pgp) of the human
multidrug-resistant (MDR) efflux pump (Shen et al., 1986;
McGrath et al., 1989), with CQR in field isolates (Foote
et al., 1990), combined with the observation that pfmdr1
mutations were not linked with CQS or CQ-resistant
progeny of the HB3 ¥ Dd2 cross (Wellems et al., 1990),
spurred a lasting debate about this gene’s role in the
mechanism and evolution of CQR (Yayon et al., 1984;
Krogstad et al., 1987; Orjih et al., 1994; Bray et al., 1998;
Sanchez et al., 2003; 2005). This incongruity led to the
suggestion that some CQS parasites may be competent
to become CQ-resistant with the acquisition of additional
mutation(s) (Foote et al., 1990). Pfmdr1 point mutations
have been associated with CQR (Foote et al., 1989; 1990;
Wilson et al., 1989; Mu et al., 2003); however, these asso-
ciations vary geographically, leaving the role of pfmdr1 in
CQR modulation and reversibility unresolved (Adagu and
Warhurst, 2001; Chen et al., 2002; Hayton and Su, 2004;
Duraisingh and Cowman, 2005; Sidhu et al., 2006; Rason
et al., 2007). PfMDR1 overexpressed in Xenopus laevis
oocytes affects transport of quinine (QN), halofantrine and
CQ in a mutation specific manner, but only wild-type
PfMDR1 affected transport of CQ in this model (Sanchez
et al., 2008). In Pichia pastoris, heterologous PfMDR1
expression catalyses drug-stimulated ATPase activity
(Amoah et al., 2007; Lekostaj et al., 2008a).
Pfcrt and pfmdr1, among other loci, interact to affect QN
dose-responses, leading us to propose that local drug
selection in different geographic regions can differentially
shape the gene interactions and their impact on a range of
drug resistance phenotypes (Ferdig et al., 2004; Sen and
Ferdig, 2004). Two recent studies, one using classical
genetics (Sa et al., 2009) and the other reverse genetics
(Valderramos et al., 2010), demonstrated the pivotal influ-
ence of the parasites’ genetic backgrounds (i.e. distinct
drug selection histories) into which the key CQR-
conferring pfcrt mutations are successfully inherited or
experimentally introduced.
A hallmark of CQ-resistant parasites is that particular
compounds can re-sensitize them to CQ, a phenomenon
termed ‘reversibility’ (Martin et al., 1987). A similar reversal
effect was first observed in MDR mammalian tumour cells
(Tsuruo et al., 1982; Rogan et al., 1984), and many classes
of compounds have now been identified that can reverse
CQR (Kyle et al., 1990; Pradines et al., 2005). One of the
earliest identified reversal agents was verapamil (VP), a
Ca2+ channel blocker indicated for the treatment of angina
pectoris, cardiac arrhythmias and hypertension. In human
tumour cells, VP-dependent chemosensitization is
believed to be mediated by Pgp (Shen et al., 1986;
McGrath et al., 1989). Because VP was found to
re-sensitize CQ-resistant P. falciparum to near CQS levels,
a Pgp efflux mechanism was considered the likely basis of
CQR (Martin et al., 1987). Three-dimensional quantitative
structure activity relationship studies generated a pharma-
cophore model for a group of tricyclic antidepressants that
reverse CQR (Bhattacharjee et al., 2002). Two hydropho-
bic, aromatic regions with a nitrogen atom acting as a
hydrogen-bond acceptor are apparently required for CQR
reversal activity (Bhattacharjee et al., 2001). This model
accommodates a variety of CQR reversal agents that span
distinct chemical classes, including VP, cyproheptadine,
ketotifen, chlorpheniramine (CLM) and citalopram (CT).
Two theories have been proposed for VP reversal of CQR:
(i) the ‘drug transporter’ hypothesis argues that VP com-
petes with CQ for target binding and perhaps drug trans-
port in resistant parasites (Martiney et al., 1995; Bray and
Ward, 1998; Sanchez et al., 2004), and (ii) VP may act on
ion transport to alter the compartmental pH and/or mem-
brane potentials to levels found in CQS parasites (Martiney
et al., 1995; Roepe and Martiney, 1999; Ursos et al., 2000;
Bennett et al., 2004). Both hypotheses are possibly rel-
evant, as drug transport by drug resistance proteins could
be due to direct and/or indirect ion-mediated co-transport
(Zhang et al., 2004). CQR reversibility by VP and the
8-aminoquinoline, primaquine (Bray et al., 2005), like CQR
itself, has been attributed to PfCRT, yet the possibility of
non-target based mechanisms suggests the interaction of
multiple transporters. Reversal agents themselves are
toxic to the parasites (Adovelande et al., 1998; Menezes
et al., 2002; 2003), but it is not known if these structurally
diverse reversal agents exert their toxic effect solely by
PfCRT or involve additional genes, nor if their inherent
anti-plasmodial effects predict the degree of reversibility of
CQR. For example, some CQ-resistant parasites such as
the South American 7G8 strain, are less responsive to the
VP reversal effect (Mehlotra et al., 2001; Sa et al., 2009). It
is not known if factors that contribute to the wide range in
CQ IC50 values among CQ-resistant field isolates, even in
the presence of identical PfCRT alleles (Mu et al., 2003),
can also influence reversibility.
PfCRT has been the overriding focus of recent studies
of CQR and its coupled reversibility by VP. To search for
additional contributing genes we measured quantitative
CQ susceptibility and its reversibility by various pharma-
cological classes of compounds, including VP, CLM, CT,
probenecid (PB) and amitriptyline (AM) in progeny of the
HB3 ¥ Dd2 genetic cross. Using 33 independent progeny,
we use quantitative trait locus (QTL) profiles to probe the
complex genetic background of the South-East Asia-
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derived CQR and its functional relationship to reversal.
This approach revealed a dynamic interplay of major and
minor shared loci highlighting gene adaptations influenc-
ing CQR, reversibility and fitness. The contribution of
pfmdr1 and a putative secondary locus on chr 7 to CQR is
reported. Pfcrt controls the vast majority of reversal by a
range of compounds. We find no evidence that pfmdr1
copy number (CN) affects CQ IC50 values; however,
co-inheritance patterns of specific pfmdr and pfcrt allele
combinations in individual progeny underscores the
complex genetic background of CQR.
Results
Quantitative effects of reversal agents, independently
and in combinations, in the parental lines
Six reversal agents – VP, CT, AM, CLM, PB and
desipramine (DES) – spanning various pharmacological
drug classes were tested in combination with CQ. Frac-
tional inhibitory concentrations (FICs) (Elion et al., 1954)
at each of the fixed molar ratios for all drug combinations
were determined for both HB3 and Dd2 to quantify the
type and degree of interactions between the reversal
agent and CQ. When plotted as isobolograms, synergistic
effects were observed for Dd2 in combinations of
CQ + VP (Fig. 1A), CQ + CT (Fig. 1B), CQ + AM
(Fig. 1D), CQ + DES (Fig. 1E) and CQ + CLM (Fig. 1F),
whereas all combinations were additive in HB3. PB was
not synergistic in Dd2 (Fig. 1C), contrary to a previous
observation in the CQ-resistant strain, V1/S (Nzila et al.,
2003); however, a recent report from this same group
(Masseno et al., 2009) revised their assessment of PB
reversal of V1/S CQR to be fivefold less synergistic. We
confirmed a linear or slightly additive relationship between
PB and CQ for both HB3 and Dd2.
Based on the comprehensive analysis of the parent
clones, a single fixed dose combination was used to con-
struct a measure of reversibility for replicate testing of 33
progeny clones. The fixed dose volumetric ratio of 9:1,
representing the lowest concentration of reversal agent
that showed synergism (Fig. 1) was used for all drug
combinations examined in the progeny (CQ + VP,
CQ + CLM, CQ + CT and CQ + AM). The starting concen-
tration for the twofold serial dilutions (see Experimental
procedures) was CQ : VP – 2.25 mM : 24.03 mM,
CQ : CLM – 2.25 mM : 71.01 mM, CQ : CT –
2.25 mM : 6.85 mM, and CQ : AM – 2.25 mM : 22.30 mM.
CQ IC50 values in HB3 and Dd2, with and without reversal
agent, demonstrated that reversal agents did not signifi-
cantly alter the CQ response in HB3 (P > 0.05, n = 5),
whereas highly reproducible reversibility (n = 18–22) was
achieved with each of the four combinations in Dd2 (Fig.
S1). The combination of CQ + AM was the most potent,





















































































Fig. 1. Isobolograms characterize drug interactions in Dd2 and HB3. Data points represent the FICs of various dose combinations of (A)
CQ + VP, (B) CQ + CT, (C) CQ + PB, (D) CQ + AM, (E) CQ + DES and (F) CQ + CLM. Each isobologram represents the interaction in both
CQ-resistant parent Dd2 (blue) and CQS parent HB3 (black). Points near the dashed line indicate an additive relationship between the two
drugs; while those above the line indicate antagonism and those below the line indicate a synergistic relationship. Synergistic interactions
were observed for most drug combinations except CQ + PB. The CQ + DES interaction plot showed weak synergism in HB3 and CQ + PB
was additive for both HB3 and Dd2.
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CQ + CT was the least potent, lowering the IC50 to an
intermediate level of 117.3  6.84 nM in Dd2. Table 1
summarizes the IC50 values for VP, CLM and CT when
tested independently. Dd2 was more sensitive to VP, CLM
and CT than HB3, with more than 6-, 45-, 20-fold differ-
ences respectively. Dd2 was only slightly more sensitive
to DES (1.4-fold) than HB3, and no difference was
observed between the parent lines for PB IC50 values
(data not shown).
Reversibility in the progeny of the genetic cross
Only the reversal agent–CQ combinations that showed
strong synergy in Dd2 were carried over into a full analy-
sis of the progeny. Mean IC50 values from VP, CLM and
CT, alone and in combination with CQ, were obtained
from five independent replicates for each of the progeny
of the genetic cross (Table S1). Values were continuously
distributed for each compound, with no clear IC50 gap
dividing the progeny into two classes that would be
expected if a single gene determined the phenotype. CQS
progeny were less sensitive to VP alone than CQ-
resistant progeny (Fig. 2A, P < 0.01), and this dichotomy
was consistent for all the reversal agents.
Among the progeny, IC50 values ranged from 18.3 to
771.0 nM for CQ and 17.8 to 105.1 nM for CQ + VP. A
relative measure, fold change, was used to assess the
degree of reversibility. For each drug combination, the fold
change distribution divided the progeny into two groups
that coincided with the inherited pfcrt allele and therefore
CQ-resistant or CQS status (Fig. 2B). CQ susceptibility in
the presence of VP for both CQS (Fig. 3A) and
CQ-resistant (Fig. 3B) progeny was strongly correlated
with CQ response in the absence of VP; however, no
significant changes were observed in CQ susceptibilities
of CQS progeny in the presence of VP (fold change
1.1  0.1, P > 0.05), whereas significantly lower IC50
values were detected in CQ-resistant parasites (6.6  1.1
fold change, P < 0.0001) in the presence of VP. The
degree of reversibility (fold change ranging from 4.7 to
8.1) was independent of the inherent CQ IC50 values in
CQ-resistant progeny (Fig. 3C) (r = 0.2, P > 0.05), and the
primary reversal mechanism for all three compounds
depended on pfcrt mutations. Highly significant correla-
tions were observed among fold changes induced by the
four compounds in CQ-resistant progeny (Table S1)
(r-values ranging from 0.89 to 0.95), indicating that a
common additional gene(s) controls the degree of
reversibility. Regression analyses of the relationships
between CQ IC50 and the potencies of the reversal agents
and fold change are provided in Table 2. Negative corre-
lations were detected between CQ IC50 values and VP,
CLM and CT IC50 values, whereas fold change resulting
from CQ + reversal agent was strongly positively corre-
lated with the CQ IC50. When these analyses were per-
formed individually on the CQS and CQ-resistant
subgroups, the relationship between fold change and CQ
IC50 was lost in both subgroups, indicating that secondary
influences on CQ IC50 values do not affect fold change.
However, positive relationships were identified for CLM
Table 1. Drug responses in the parents of the genetic cross.
Drugs n
Mean  SEM
Dd2 IC50 (nM) n
Mean  SEM
HB3 IC50 (nM)
VP 21 2303  245 5 14 307  3442
CLM 22 1976  238 5 90 446  1902
CT 21 2082  200 5 42 276  1771
CQ 18 422  25.0 5 27.2  0.94
CQ + VP 22 82.8  4.42 5 25.9  0.57
CQ + CLM 22 71.7  3.71 5 20.6  5.19
CQ + CT 21 117  6.84 5 25.5  0.78
CQ + AM 22 59.2  3.12 5 25.4  0.91
Fig. 2. Ranked plots showing phenotype distributions for CQ with and without VP.
A. Ranked distribution for VP response against CQ response in the cross. VP response is continuously distributed and inversely related to CQ
response. Progeny that had high VP IC50 values had lower CQ IC50 values. This negative relationship was consistent with all other reversal
agents tested.
B. Ranked distribution for CQ response against fold change in the presence of VP. Fold change partitions the drug responses into two groups
(CQS and CQ-resistant) depending on the HB3 and Dd2 pfcrt allele.
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and CT potencies with CQ IC50 in both CQS and
CQ-resistant progeny, suggesting that secondary genetic
determinants of quantitative CQ susceptibility in these
subgroups may influence CLM and CT response.
QTL analysis of drug responses
Genome-wide QTL scans for VP, CLM, CT, CQ and
CQ + VP responses are presented in Fig. 4. VP, tested
independently (Fig. 4A), revealed a significant chr 7 QTL
at 20.2 cM [log of odds (LOD) = 6.9] in the region of pfcrt.
In addition, a suggestive QTL was identified on chr 5
(LOD = 2.3) that mapped to the marker at position
68.8 cM in the region of pfmdr1. CLM (Fig. 4B) and CT
(Fig. 4C), tested independently, each revealed two QTL: a
significant QTL on chr 7 (20.2 cM, LOD = 47 and 28
respectively) and a suggestive QTL on chr 5 (68.8 cM,
LOD = 2.7 and 2.9 respectively). The substantial coinci-
dence of the chr 5 (pfmdr1) and chr 7 (pfcrt) QTL for VP,
CLM and CT was consistent with a relationship between
A B C




































Fig. 3. Relationship between CQ IC50 and CQ with VP response in CQS and CQ-resistant progeny.
A. Relationship between CQ response with and without VP in CQS parasites. CQS progeny exhibit a strong positive relationship between CQ
response with and without VP (r = 0.80, P < 0.0001), although this relationship reflects unchanged responses.
B. Relationship between CQ response with and without VP in CQ-resistant parasites. CQ-resistant progeny exhibit a strong positive
relationship between CQ response with and without VP (r = 0.84, P < 0.0001), resulting from a significant reduction in CQ response in the
presence of VP.
C. Relationship between CQ response and fold change of CQ response in the presence of VP. Correlation analysis detects no significant
relationship between CQ response in CQ-resistant parasites and the fold change resulting from CQ + VP combination (r = 0.2, P > 0.05).
Table 2. Correlation analyses for CQ response versus reversal agent potency and fold change in CQS and CQR progeny.
All progeny








r -0.72 -0.95 -0.92 0.98 0.98 0.98 0.98
P-value *** *** *** *** *** *** ***
CQS progeny








r 0.37 0.49 0.53 0.32 0.42 0.34 0.45
P-value 0.12 0.03 0.02 0.19 0.07 0.15 0.06
CQR progeny








r 0.48 0.55 0.75 0.15 0.02 0.08 0.04
P-value 0.06 0.03 0.0001 0.59 0.93 0.78 0.89
*** P < 0.0001.
VP, CLM and CT represent IC50 values of reversal agents when used alone (i.e. potency).
Correlation analysis reported as Pearson’s correlation coefficient reported as an r-value, and the P-value determining if significantly deviating from
zero.
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CQ + VP (fold change)
Fig. 4. Genome-wide QTL scans. Three significance thresholds were determined by permutation testing. Highly significant (P < 0.01),
significant (P < 0.05) and suggestive (P < 0.63) LOD scores are represented by horizontal lines on each scan. The abscissae show
chromosomal location (14 chromosomes), where the width of the chromosome number is proportional to the number of markers. All traits, VP,
CLM, CT, CQ and CQ + VP map to chr 7 (20.2 cM) in the region of pfcrt. A suggestive QTL on chr 5 (68.8 cM) in the region of pfmdr1 was
detected for VP, CLM and CT.
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these two loci in controlling sensitivities to VP, CLM and
CT. The genome-wide scan for CQ sensitivity detected a
single highly significant QTL with a LOD = 39 (Fig. 4D).
Fold change resulting from combining each reversal
agent with CQ revealed a single shared QTL on chr 7
(20.2 cM) with even higher LODs than were observed for
CQ response (e.g. Fig. 4E).
Allelic effects for the chr 5 (68.8 cM) and chr 7 (20.2 cM)
loci (Fig. 5A and B respectively) indicated that higher
IC50 values for VP, CLM and CT drug responses were
associated with the HB3 allele at both loci. For CQ
response, the Dd2 allele on chr 7 (20.2 cM) was associ-
ated with a higher IC50 and a greater fold change in the
presence of a reversal agent. Figure 5C and D shows an
overlay of QTL highlighting the shared QTL on chrs 5 and
7 respectively. This shows that at least two, and probably
more loci influence the response to reversal agents by
themselves, commensurate with the continuous distribu-
tion of those traits. However, CQ response reversibility is
solely dependent on the chr 7 genetic effect that gener-
ates a two-class phenotype as a result of mutations in
pfcrt (Fidock et al., 2000; Cooper et al., 2002; Sidhu et al.,
2002). To investigate the genetic basis of the highly cor-
related degree of reversibility induced by VP, CT, AM and
CLM in CQ-resistant progeny, measured as fold change,
we conducted QTL scans directly on this subclass of
progeny. A QTL peak on chr 11 (48.8 cM) in the region of
marker C12M42 at 701 403 bp, passed the suggestive
LOD threshold for fold change with all four compounds
(data not shown).
Identification of genetic loci affecting the range of
susceptibilities in CQ-resistant progeny
The rank order distribution of CQ response in the progeny
is bimodal, as originally demonstrated by Wellems et al.
(1990), and as is expected for a single major gene. In that
early work, microscopy-based evaluation of parasi-
taemias showed identical IC50 values for eight CQS and
eight CQ-resistant progeny, and these two discrete
classes did not segregate with the pfmdr1 marker allele,
proving that in the HB3 ¥ Dd2 progeny pfmdr1 was not
the determinant of CQR. Here we used 33 progeny
and multiple independent replications of radiolabelled-
hypoxanthine (HX) incorporation to observe continuous
distributions of quantitative CQ susceptibility within both
the CQS (18–38 nM) and CQ-resistant (266–771 nM)
subgroups (Fig. 6A). We examined only the CQ-resistant
progeny for further analyses to specifically map QTL
contributing to the wide range of CQ IC50 values in the
resistant class inheriting mutant pfcrt. This approach
eliminates the contribution by pfcrt effect because each of
the CQR progeny carried the identical Dd2 pfcrt allele. We
identified two secondary loci, on chrs 5 and 7. The chr 5
QTL again mapped to 68.8 cM in the region of pfmdr1,
with a LOD = 2.5, and the novel chr 7 QTL mapped to
5.8 cM with a LOD = 2.0 (Fig. 6B and Table S2). The
allelic effect plots indicate that the chr 5 (68.8 cM) HB3
allele and the chr 7 (5.8 cM) Dd2 allele contributed to the
highest CQR IC50 values (Fig. 6C). Because we observed
a suggestive chr 5 QTL peak in this subset of progeny, we
Fig. 5. Allele effects at peak markers for QTL detected on chr 5 and 7. Effects of the Dd2 and HB3 alleles for response to VP, CLM, CT and
CQ at peak markers for QTL: (A) chr 5 (68.8 cM) and (B) chr 7 (20.2 cM). Higher trait values were observed for the HB3 alleles at both QTL
for the reversal agents tested independently, whereas the higher trait value for CQ response and fold change (degree of reversibility) were
observed with the Dd2 allele. (*P < 0.05, **P < 0.001 and ***P < 0.0001.) Overlaid QTL for VP (blue), CLM (red) and CT (black) for (C) chr 5
and (D) chr 7 respectively.
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further examined the relationship between pfmdr1 and the
Dd2-type pfcrt allele by employing the statistical method
described by Sa et al. (2009) to directly test the influence
of different pfmdr1 alleles on CQ IC50 values. Four differ-
ent allele pair combinations were possible for pfmdr1 and
pfcrt: D5D7, H5D7, D5H7 and H5H7 (D represents an allele
inherited from Dd2, and H represents an allele inherited
from HB3). The pfmdr1 locus significantly influenced the
Fig. 6. CQ drug responses in the progeny identifying additional QTL effects contributing to extreme CQ drug response.
A. Rank order plot of CQ response in the progeny of the cross. A greater than 10-fold increase in IC50 divides the progeny into CQS and
CQ-resistant subsets. As a trait, this large difference maps to pfcrt on chr 7 and explains greater than 95% of the total variation in the cross. A
steady increase in CQ-resistant progeny is observed ranging from 266.5 to 771.0 nm.
B. Genome-wide QTL scan for CQ response in CQ-resistant progeny. This QTL analysis identifies two suggestive QTL (P < 0.63): one on chr
5 (68.8 cM) in the region of pfmdr1 and one on chr 7 (5.8 cM).
C. Allele effects of peak markers of CQR QTL. Inheritance of the Dd2 allele at the QTL on chr 5 (68.8 cM) confers low-level CQR, whereas
the HB3 allele corresponds to higher CQR levels. An opposite pattern is seen for the chr 7 QTL peak marker (5.8 cM). A combination of H5D7
alleles combined with Dd2-type pfcrt results in the highest CQR levels (*P < 0.05, **P < 0.001, *** P < 0.0001).
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CQ IC50 only in CQ-resistant progeny; we detected a
1.57-fold shift in CQ susceptibility (P < 0.01) depending
on the source of the pfmdr1 allele in combination with
mutant pfcrt. CQR progeny with the H5D7 combination
have significantly higher IC50 values than D5D7 (Fig. 6C).
Because this difference was not detected in a recent
study (Sa et al., 2009), we validated our findings. The rank
order of CQ IC50 values, 1BB5 > QC03 > 3BD5 in our
study, contributed most to the differing results between
the two studies. Because we use CQ as a control drug in
our ongoing drug assays, four independent replicated
analyses of the complete progeny set were available in
our database and each demonstrated the same statisti-
cally significant rank order (1BB5 > QC03 > 3BD5) (data
not shown). We also reanalysed CQ IC90 values from the
HB3 ¥ Dd2 cross (Ferdig et al., 2004) using the same
alternative statistical model outlined here and found a
1.4-fold CQ IC90 difference (P < 0.01) between D5D7 and
H5D7 progeny, with the latter combination most resistant.
Pfmdr1 CN and observed allele combinations in the
progeny clones
Pfmdr1 CN was determined for all progeny (Table S3).
The Dd2 parent has three copies while HB3 has a single
copy. We observe nine progeny with two copies and three
additional progeny with the Dd2 pfmdr1 allele and CN = 1.
Non-parental CN were reported previously for partial sets
of HB3 ¥ Dd2 progeny (Wellems et al., 1990; Rohrbach
et al., 2006) and increased CN shows increased expres-
sion levels of PfMDR1 (Wilson et al., 1989; Rohrbach
et al., 2006). Here we confirm and extend the findings of
the inherited variation in CN, noting that the HB3 pfmdr1
allele is always present as a single copy, while the Dd2
allele varies from one to four copies across the progeny
set. We have confirmed the in vitro stability of CN by
culturing 10 progeny clones for 30–45 replication cycles
and observing no change in CN (data not shown).
It is difficult to determine the direct impact of pfmdr1 CN
on CQ IC50 values because the allele effects cannot be
precisely separated from the CN effects in progeny car-
rying one versus two copies. However, a direct compari-
son of IC50 values of CQ-resistant parasites with two
versus three or more copies, all of which contain Dd2 pfcrt
and pfmdr1 alleles, reveals no correlation (r = -0.02) and
no difference in the mean IC50 values (P = 0.59). Further-
more, we statistically removed the contribution of pfcrt
and compared the residuals of mean CQ IC50 values in the
complete progeny set and found that CN (1 versus > 1,
P = 0.044) accounted for somewhat less of the residual
variation than point mutations alone (HB3 versus Dd2,
P = 0.02). Consequently, our data do not support a role for
CN in influencing CQ susceptibility. However, several
observations support co-adaptation between pfmdr1 CN
and pfcrt. Inherited combinations of these loci in the
progeny clones suggest an influence on fitness as sur-
mised from the combinations that exist among the
progeny: (i) of 33 progeny analysed, 15 inherited the Dd2
pfmdr1 allele, but only three retained the full complement
of three copies; each of these three carries the mutant
pfcrt. Twelve of 15 progeny with the Dd2 pfmdr1 allele lost
at least one pfmdr1 copy in the establishment of the stable
progeny clonal lines, (ii) all progeny carrying the single
copy Dd2 pfmdr1 allele are CQS, carrying the wild-type
pfcrt, and (iii) all five of the progeny with the D5H7 allele
combination carry fewer than three copies. High CN is
maintained only in the context of its co-selected mutant
pfcrt partner, and CQS pfcrt is never paired with three
copies of pfmdr1 (Table S3).
Binding of a high affinity CQ analogue to PfMDR1
Recently, the CQ binding site for wild-type PfCRT was
defined using a novel photoaffinity chloroquine analogue,
azido-biotinylated chloroquine (AzBCQ) (Lekostaj et al.,
2008b). Using this same method and overexpression of
recombinant PfMDR1 (Amoah et al., 2007; Lekostaj et al.,
2008a), we tested whether the high-affinity AzBCQ probe
would bind to 3D7 (wild type), Dd2 and 7G8 isoforms of
purified recombinant PfMDR1 protein reconstituted into
proteoliposomes (PLs) as recently described elsewhere
(Pleeter et al., 2010). Figure 7 demonstrates that binding
of AzBCQ to PfMDR1 reveals CQ affinity for PfMDR1. A
40- to 50-fold molar excess of CQ reduces efficiency of
AzBCQ photolabelling to < 30% of control for 3D7 and
Dd2 isoforms of PfMDR1 (Fig. 7A; lanes 2 versus 1 and 5
versus 4 respectively). Apparent CQ affinity for the 7G8
isoform is slightly reduced (competition to < 40% of
control, Fig. 7A; lane 8 versus 7) relative to the other
isoforms. Averaged over three experiments and two inde-
pendent PL preparations for each isoform of PfMDR1, we
did not identify pronounced VP competition for AzBCQ
photolabelling to any isoform of PfMDR1 (Fig. 7C), in con-
trast to our earlier demonstration of VP competition for
AzBCQ photolabelling of the 3D7 and Dd2 isoforms
PfCRT (Lekostaj et al., 2008b).
Discussion
After decades of remarkable success, CQ is no longer
used against P. falciparum in most regions of the world
due to the evolution of resistance (Wellems and Plowe,
2001). Selection by CQ was the first step towards the
evolution of modern-day MDR parasites, yet questions
remain about how CQR evolved and why CQR parasites
persist long after CQ disuse. Answers to these questions
will inform a more strategic development and deployment
of drugs against MDR parasites.
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The classical genetic approach relies on Mendelian
recombination and segregation to shuffle the naturally
evolved allele combinations that have been fine-tuned by
selection pressures on the parental genomes. By crossing
two parents with distinct evolutionary histories, e.g. drug
selection pressures applied in different geographic
regions, the divergent signatures of selection in these
genomes can be identified by QTL mapping. The strength
of this approach was illustrated in a recent study compar-
ing the genetic control of CQ and amodiaquine suscepti-
bilities in progeny from two crosses between parents
carrying a range of drug selection histories (Sa et al.,
2009).
Here, we rely on the P. falciparum HB3 ¥ Dd2 genetic
cross (Wellems et al., 1990) to dissect the quantitative
response to CQ, and to identify genetic loci that influence
the reversibility of CQR. HB3 is a CQS parasite derived
from Honduras. The progenitor of Dd2 was derived from a
Laotian patient who failed CQ therapy (Campbell et al.,
1982), and this line also has high-level resistance to
pyrimethamine. Dd2 was cloned from W2-mef which was
selected in the laboratory by mefloquine (MQ). Conse-
quently, the MDR Dd2 genome has been shaped by
sequential drug selections and carries the South-East
Asia-derived CQ-resistant PfCRT haplotype, referred to
here as CVIET (amino acid positions 72–76).
A wide range of compounds can reverse CQR. By
adapting the QTL methodology to compare a range of CQ
chemosensitizers, we explored the genetic components
of reversibility, represented by fold change of CQ IC50
induced by several reversal agents. Furthermore, we
examined the potencies of the individual reversal
compounds. Continuous distributions were observed for
the inherent potencies of VP (Fig. 2A), CLM and CT and
susceptibility to these compounds was inversely corre-
lated with CQ response. Previously VP was shown to
have greater potency against CQ-resistant parasites
(Gerena et al., 1992), as have various antihistaminics
(Peters et al., 1989; 1990) and amantadine (Johnson
et al., 2004). Models predict binding of amantadine, a
proton channel blocker, to the putative PfCRT pore of
CQ-resistant parasites that could interfere with the trans-
port of a critical substrate, resulting in parasite death
(Johnson et al., 2004; Wellems, 2004). This and other
observations suggest that specific PfCRT binding by
reversal agents underscores the potential of this trans-
porter as a drug target. The continuous phenotype distri-
butions indicate that multiple genes contribute to these
traits. QTL analyses of the direct responses to VP, CLM
and CT (Fig. 4A–C) identified two loci shared by all three
reversal agents. The QTL on chr 5 maps to a marker at
68.8 cM in the region of pfmdr1 (Fig. 5C) and the QTL on
chr 7 maps to the marker at 20.2 cM in the region of pfcrt
(Fig. 5D). These shared QTL indicate that parasite sus-
ceptibility to these structurally and pharmacologically dis-
tinct compounds is controlled by similar mechanisms that
depend on both pfcrt and pfmdr1. The HB3 allele at both
loci is associated with higher drug IC50 values in the
progeny (Fig. 5A and B). No other statistically significant
loci were detected for these compounds, leaving unclear
where additional factors controlling these complex traits
reside.
In contrast to the individual effects by these com-
pounds, genome-wide scans for reversibility maps to a
single locus on chr 7 (20.2 cM) in the region of pfcrt. All
combinations [CQ + VP (Fig. 4E), CQ + CLM, CQ + CT
and CQ + AM] had exceptionally high LOD scores, indi-
cating that reversibility of CQR is predominantly deter-
mined by pfcrt for all drug combinations. This observation
is consistent with the recent observation that VP inhibits
CQ transport (Martin et al., 2009; Paguio et al., 2009) and
competes for labelling of recombinant purified PfCRT by a
photoaffinity CQ analogue (Lekostaj et al., 2008b). Corre-
Fig. 7. Competition of AzBCQ labelling of 3D7, Dd2 and 7G8
isoforms of PfMDR1 by CQ and VP. In each photolabelling
experiment, AzBCQ was present in a probe : protein molar ratio of
about 100:1. PfMDR1 was labelled at various drug : AzBCQ molar
excess ratios indicated below. All blots are representative of
experiments conducted at least three times on at least two
preparations of purified PLs wherein similar data were observed.
Lanes 1–3 are 3D7 PfMDR1, lanes 4–6 are Dd2 PfMDR1 and
lanes 7–9 are 7G8 PfMDR1. Top panels: Streptavidin-HRP
detection of AzBCQ photolabelling with CQ competition. First lanes
of each isoform have no competitor; second lanes of each isoform
have 48-fold excess CQ; third lanes of each isoform have 80-fold
excess CQ. Middle panels: Anti-PentaHis-HRP detection of 6His
tag present in all isoforms. Bottom panels: Streptavidin-HRP
detection of AzBCQ photolabelling with VP competition. First lanes
have no competitor; second lanes have 20-fold excess VP; third
lanes have 40-fold excess VP.
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spondingly, that we observed no effect by pfmdr1 on
reversibility agrees with the lack of significant disruption
by VP of PfMDR1–AzBCQ binding (Fig. 7). Our observa-
tion of a direct determination of reversibility by pfcrt muta-
tions concurs with the recent suggestion that CQ reversal
agents are substrates for PfCRT and possibly inhibit CQ
transport by a competitive mechanism (Lehane and Kirk,
2010). Our findings are restricted to the CVIET pfcrt allele
carried by the Dd2 parent; other reports indicate that VP
has less potency as a CQR reverser in the context of the
SVMNT allele (Mehlotra et al., 2001; Sa et al., 2009),
perhaps because VP is not a substrate for this form of
pfcrt (Lekostaj et al., 2008b; Lehane and Kirk, 2010). We
also identified a candidate locus on chr 11 controlling the
four- to eightfold increase in CQ susceptibility induced by
all four reversal agents. Although this is a modifying locus
in HB3 ¥ Dd2 progeny, it could point to a gene or pathway
that plays a prominent role in the more subtle form of
reversal observed in 7G8 that is not strongly linked to
PfCRT mutations.
The HB3 ¥ Dd2 P. falciparum genetic cross (Wellems
et al., 1990) was generated to localize the determinant of
CQR. For those studies, CQ susceptibility was treated as
a bimodal trait such that each progeny was assigned to a
subclass – CQS or CQ-resistant. This approach is effec-
tive for mapping a major genetic determinant and led to
the identification of the chr 7 locus (Wellems et al., 1991),
followed by positional cloning of pfcrt and eventual iden-
tification of the critical K76T mutation (Su et al., 1997;
Fidock et al., 2000). QTL analyses relies on precise mea-
surement of continuous phenotypes and can reveal both
major and minor gene contributions and define the inter-
actions among the identified loci (Ferdig et al., 2004). QTL
analyses of CQ-resistant progeny remove the dominant
pfcrt effect and point to two suggestive QTL [on chr 5
(68.8 cM) and on chr 7 (5.8 cM)] that account for ~70% of
the phenotypic variance inherited in CQ-resistant individu-
als (Fig. 6B). We found that the pfmdr1 locus significantly
influenced CQ IC50 values in CQ-resistant progeny, pro-
ducing a 1.57-fold shift in CQ susceptibility. The effect of
pfmdr1 in generating distinct levels of CQR in the
HB3 ¥ Dd2 cross is weaker than the nearly twofold shift
induced in the progeny from the 7G8 ¥ GB4 cross that
carries the 7G8 pfcrt allele from South America (SVMNT)
(Sa et al., 2009).
The insight of Sa et al. that different drug use in different
geographic regions will result in differentially tuned allele
combinations may also be relevant here. Specifically,
these authors propose that pfmdr1 mediates a more
stable, persistent form of CQR in South America and that
this advantaged pfmdr1 ¥ pfcrt allelic combination may be
induced in Africa by increased use of amodiaquine. The
observation that low-level QN resistance in the HB3 ¥ Dd2
cross exhibited a positive correlation with CQ IC90 values in
CQ-resistant parasites led to the suggestion that second-
ary loci selected by QN pressure, including pfmdr1, could
incrementally influence CQ and other drug susceptibilities
through a complex adaptive role among various polymor-
phisms (Ferdig et al., 2004). That is, amplification of and
site-specific changes in pfmdr1 associated with QN sus-
ceptibility (Cowman et al., 1994; Reed et al., 2000) could,
in turn, have influenced the stability of CQR in South-East
Asia and Africa through co-adapted allele combinations.
We observed that CQ-resistant progeny that inherited
an HB3 allele at pfmdr1 produced the highest CQ IC50
values (Fig. 6C). This observation concurs with the obser-
vation that 7G8 ¥ GB4 progeny that inherited the GB4
(CVIET) PfCRT allele show a smaller shift in CQR levels
(1.4-fold) induced by the co-inherited pfmdr1 allele (Sa
et al., 2009). In both crosses, it is the mismatched pfmdr1
allele – the allele not originating from the CQ-resistant
parent with the CVIET haplotype – that is associated with
the highest levels of CQR among the respective progeny.
Importantly, this is in contrast to the situation for the 7G8
form of pfcrt (SVMNT) that produces its highest levels of
CQR when matched with its co-evolved 7G8 pfmdr1
partner. Notably, the levels of resistance produced by
SVMNT are considerably lower than those produced by
CVIET PfCRT, which originated in South-East Asia and
later spread to Africa (Wootton et al., 2002). The
unmatched allele combination, GB4 pfmdr1–7G8 pfcrt,
exhibited a strikingly low level of CQR, with nearly 2.5-fold
lower IC50 values than the average CVIET progeny,
perhaps near the limit of surviving therapeutic CQ doses.
Considered in total, these observations imply that pfmdr1
and pfcrt are co-evolved in the respective CQ-resistant
parent genomes to optimize cell function and compensa-
tion rather than to maximize CQ IC50 levels.
Analogous to the persistence of SVMNT CQR pfcrt
alleles in South America (Contreras et al., 2002; Vieira
et al., 2004), CQ-resistant parasites continue to predomi-
nate in Thailand more than 25 years after cessation of CQ
therapy (Brockman et al., 2000; Price et al., 2004; Mu
et al., 2005), even while carrying the CVIET form of pfcrt
that has been suggested to be less fit in some genetic
contexts. For example, CQ sensitivity has re-emerged in
Malawi, where CQR was once widespread but CQ is no
longer used (Kublin et al., 2003; Mita et al., 2003; Laufer
et al., 2010), and in Hainan, China, where over a 10-year
period CQR prevalence decreased from 98% to 61% (Liu
et al., 1999). In these cases, CQ sensitivity returned
steadily by re-integration of the complete CQS genomes,
not by point mutant reversions that would be predicted for
a single-gene resistance with strong fitness costs.
Because the sufficiency of introduced pfcrt mutations to
induce CQR was tested only in certain genetic back-
grounds (Sidhu et al., 2002), Hastings et al. (2002) noted
that the definitive experiment would require introduction of
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these mutations into a series of different genetic
backgrounds. Valderramos et al. recently demonstrated
the critical role of genetic background on the ability of the
7G8 pfcrt allele to confer CQR (Valderramos et al., 2010);
they induced phenotypes in a variety of CQS back-
grounds that ranged from high-level CQR (GC03, a
progeny of the HB3 ¥ Dd2 cross) to no change in IC50 but
an increased rate of recrudescence (D10, Papua New
Guinea). Parasite lines with identical pfmdr1 alleles trans-
fected with the same pfcrt allele showed distinct
CQ-resistant phenotypes, underscoring the role of genes
other than pfmdr1 and pfcrt. Moreover, the Dd2 pfcrt allele
could not be used to successfully transform three different
CQS background, 3D7, D10 and HB3. Only GC03, carry-
ing half of its genome from Dd2, has been successfully
transfected with the Dd2 pfcrt, giving rise to high-level
CQR. Because HB3 and GC03 carry identical single copy
pfmdr1 alleles, we can again infer that an additional
gene(s), co-selected in the Dd2 parent, must contribute to
the competency of a CQS parasite to support the large
effect CQR mutations. Notably, the mutational steps that
gave rise to the few independently evolved CQR origins
remain unknown. One possible candidate is an epistatic
partner of pfcrt residing in the chr 6 locus was shown
previously to regulate low-level QN resistance and asso-
ciate with slow in vitro expansion rates of progeny inher-
iting the HB3-type chr 6 and Dd2-type pfcrt loci (Ferdig
et al., 2004).
Dd2 and HB3 differ both in point mutations and in CN
for pfmdr1: Dd2 (86Y, 184Y and 1042N) maintains three
copies of pfmdr1, while HB3 (86N, 184F and 1042D)
maintains a single copy. In an effort to evaluate the rela-
tive contribution of point mutations and CN on CQ sus-
ceptibility, we determined CN for the complete progeny
set. Previous studies demonstrated that increased copies
of pfmdr1 coincided with an increase in PfMDR1 protein
levels (Rohrbach et al., 2006). Allelic exchange studies to
understand the role of amino acid changes in PfMDR1
have been limited to the carboxyl region that includes
1042N; replacement of the pfmdr1 3′ polymorphisms in
CQ-resistant progeny 3BA6 with the Dd2- allele
(D1042N) did not significantly alter CQ response (Sidhu
et al., 2005) but did not rule out that either the 5′ region
(86Y, 184Y) and/or pfmdr1 CN influence CQR levels. The
placement of D10 pfmdr1 3′ polymorphisms in the 7G8
background led to a twofold decrease in CQ response
(Reed et al., 2000). When pressured with CQ, parasites
with multiple pfmdr1 copies lose extra copies of the gene
(Barnes et al., 1992; Peel et al., 1994), with no other
mutation in pfmdr1 or pfcrt, suggesting that excessive
copies may have a fitness cost. We found no difference in
CQR levels attributable to CN. Moreover, most progeny
with the Dd2 pfmdr1 allele do not carry the parental
complement of three copies. CN change is commonly
reported in response to in vitro drug pressure (Wilson
et al., 1989; Barnes et al., 1992; Chavchich et al., 2010),
and a reduction in CN has been observed after removal of
artelinic acid pressure (Chen et al., 2010); the rate of CN
loss and the final stable numbers of copies is a charac-
teristic of individual parasite lines. We have observed that
CN is stable in long-term culture in these progeny, sug-
gesting that the relationship of allele combinations at
pfmdr1 and pfcrt is fine-tuned. High CN thrives only in the
context of its co-evolved genome that includes Dd2-type
pfcrt, whereas CQS pfcrt prefers a single copy of pfmdr1
(Table S3).
Pfmdr1 knockdown by gene disruption for FCB (86Y,
184Y and 1042N) showed no significant changes in CQ
susceptibility (Sidhu et al., 2006). Association studies in
natural CQ-resistant populations have identified a signifi-
cant role for pfmdr1 86Y and pfcrt 76T in CQR (Babiker
et al., 2001; Mittra et al., 2006), but the presence and
strength of these associations varies geographically. The
frequencies of both these alleles are on the rise in regions
of India under intense CQ selection (Mittra et al., 2006).
However, in Thailand, where CQ is no longer used and
MQ pressure led to increased pfmdr1 CN, CQ-resistant
parasites uniformly carry pfmdr1 86N (Price et al., 2004).
An apparent conflict exists between 86Y and increased
CN such that CN increases often associated with selec-
tion by MQ, artemisinin and lumefantrine, coincides with
the loss of 86Y (Uhlemann et al., 2007). It is unusual to
find the 86Y mutation with increased CN, but it has been
reported in natural isolates collected prior to emergence
of MQ resistance (Looareesuwan et al., 1992; Uhlemann
et al., 2005; Sidhu et al., 2007). Both point mutations in
pfmdr1 and increased CN have been widely associated
with fitness costs during asexual, erythrocytic growth in
the absence of drug pressure in field isolates (Osman
et al., 2007), allelic replacements (Hayward et al., 2005)
and drug selected mutants (Preechapornkul et al., 2009).
It may be that the coincidence of 86Y and increased
copy number is a transitional state that has been captured
in the Dd2 line by in vitro MQ selection on W2. In the
HB3 ¥ Dd2 progeny, the combination of PfMDR1 86Y and
PfCRT 76T confers only low-level CQR and the progeny
that inherited 86N combined with a single copy of pfmdr1
have the highest CQR levels. This is consistent with the
co-adapted combination of Dd2 alleles at these two loci
reflecting a trade-off between the level of CQR and
fitness.
Classical genetics and QTL mapping can compliment
gene manipulations using transfection methods to explore
the basic biology of CQR. Pfcrt mutations are well known to
be at the centre of CQR and its reversibility; however,
accumulating evidence points to an important role for
additional factors that influence these traits as well as
parasite fitness. We show that many structurally distinct
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reversal agents restore CQ susceptibility through a
PfCRT mechanism. Furthermore, although pfcrt is the
determinant of large phenotypic differences between
CQ-resistant and CQS parasites, secondary loci can be
identified for CQ susceptibility and reversibility. These
loci can point to genes that may interact with the endog-
enous function of pfcrt or may cause effects through
indirect physiological mechanisms. Understanding
these interacting/alternative pathways and their co-
selection by drug may illuminate the evolutionary path to
CQR and, more importantly, refine strategies to limit new
resistances.
Experimental procedures
Parasites, genotypes and culturing
The HB3 (Honduras) and Dd2 (Indochina) clonal parental
isolates and 35 clonal progeny lines are from the same cross
previously used to construct the P. falciparum high-resolution
genetic linkage map (Wellems et al., 1990; Su et al., 1999).
Leukocyte-free human red blood cells (Indiana regional blood
centre) were suspended in complete medium [RPMI 1640
with L-glutamine (Invitrogen), 50 mg l-1 hypoxanthine and
25 mM HEPES; 0.5% Albumax I (Invitrogen), 10 mg l-1 gen-
tamicin and 0.225% NaHCO3] at 4% haematocrit and grown
at 37°C in six-well culture plates, placed in a sealed environ-
mental chamber (Billups-Rothenberg), and gassed daily
(mixture of 5% CO2, 5% O2 and 90% N2). Lines were cultured
for at least three cycles after thawing with a minimum dou-
bling of parasitaemia each 48 h cycle, prior to initiation of
drug assays. No attempt was made to synchronize parasite
cultures; however, the process of thawing yielded partially
synchronous parasite stages. Dilutions to initiate assays
were made from cultures between 1% and 5% parasitaemia
consisting of greater than 75% ring stages. To minimize
chances of genotype–phenotype shifts resulting from muta-
tion accumulation, parasite cultures were carried for a
maximum of 6 weeks and replicate testing was conducted on
stocks closest to the original progeny (stock cultures are
frozen from short-term cultures).
Drug response assays
Drug stocks of chloroquine diphosphate (Sigma-Aldrich),
verapamil hydrochloride (Sigma-Aldrich), chlorpheniramine
maleate (Sigma-Aldrich) and amitriptyline hydrochloride
(Sigma-Aldrich) were made in deionized water. A stock solu-
tion of citalopram hydrobromide (Fisher Scientific) was made
in 100% ethanol. Stock solutions of probenecid (Avocado
Research Chemicals) and desipramine (Sigma-Aldrich) were
made in DMSO. All solutions were stored at -20°C until use.
Dilutions from these stocks were made in low-hypoxanthine
complete medium (low-HX CM; RPMI 1640 with L-glutamine,
2.94 mM HX and 50 mM HEPES; 0.5% Albumax I, 10 mg ml-1
gentamicin and 0.225% NaHCO3). Drug assays based on
[3H]-HX incorporation were performed as previously
described (Ferdig et al., 2004); each biological replication
was conducted independently on different days for each
parasite line. For inclusion in the assay, each progeny clone
was genotyped using a panel of 10 MS markers to ensure
clonality and confirm identity.
Per cent inhibition was calculated by the formula:
100 cpm at lowest concentration of drug
cpm of treated 
× ( ) −[
sample cpm at lowest concentration of
drug cpm at hig
( )] ([
) − hest concentration of drug .( )]
IC50 values were determined by fitting data to a non-linear
sigmoidal dose–response curve (variable slope) using
GraphPad Prism v4.0 software. Log transformed mean
dose–response values were obtained from 5 to 22 indepen-
dent measurements and were used for QTL analysis.
Isobologram analysis
To determine the presence and degree of reversibility in the
parents of the genetic cross, twofold serial dilutions of the
drug combinations of CQ and reversal agents were prepared
using fixed ratios. The starting concentrations of reversal
agents for the serial dilutions were adjusted to approximately
centre the IC50 doses in the range tested. The following
CQ : reversal agent volumetric ratios were used: 10:0, 9:1,
8:2, 7:3, 5:5, 3:7, 2:8, 1:9 and 0:10. The first and last ratios
include only one drug, either CQ or the reversal agent. FICs
were determined for each drug combination for both HB3 and
Dd2 using the formula:
IC  of drug A, tested in combination IC  of drug A,
tes
50 50( ) (




) + ( )
drug B, tested alone .( )
Additivity was defined as a FIC = 1 and synergism (revers-
ibility) was defined as a FIC of  0.5 (points lying below the
diagonal line of additivity). The fixed dose ratio with the lowest
concentration of reversal agent that showed a synergistic
interaction with CQ was used for tests in the progeny.
QTL analyses
Genome-wide scans were performed using R/QTL (Broman
et al., 2003) to detect single and interacting QTL associated
with drug responses in the HB3 ¥ Dd2 genetic cross. Drug
responses were log transformed to approximate a normal
distribution. Genome-wide significance thresholds were
determined by permutation testing (n = 1000 permutations)
(Doerge and Churchill, 1996) and the strength of linkage of a
locus to the trait was expressed as a LOD score. Loci that
exceeded the 99th percentile (P < 0.01), 95th percentile
(P < 0.05) and 37th percentile (P < 0.63) were used to iden-
tify highly significant, significant and suggestive QTL
respectively. The combined effects of all QTL detected for
each trait were determined by multiple regression analysis for
all significant and suggestive QTL. Other statistical analyses
were performed using GraphPad Prism v4.0. Allele effects
were determined by calculating the phenotypic mean at the
peak marker for each of the two possible genotypes.
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Copy number determination
Pfmdr1 copy number was determined by TaqMan real-
time PCR using an ABI 7700 as reported previously
(Rohrbach et al., 2006). The pfmdr1 probe was FAMTM
(6-carboxyfluorescein) labelled at the 5′ end, and the a-tubulin
control probe was VICTM labelled. Forty cycles were per-
formed and fluorescence data were expressed as normalized
reporter signals, calculated by dividing the amount of reporter
signal by the passive reference signal. The assay was repli-
cated four independent times and normalized to HB3.
Purification of recombinant PfMDR1 and reconstitution
into PLs
High-level expression of various isoforms of PfMDR1 with
C-terminal hexaHis detection tags via the pPICZc expression
vector (Invitrogen) in P. pastoris has been reported previously
(Amoah et al., 2007; Lekostaj et al., 2008a). Yeasts were
grown under standard conditions, induced with 0.5% metha-
nol medium for 21 h, mechanically lysed via a modified glass
bead method and membranes harbouring PfMDR1 were iso-
lated as described (Fritz et al., 1999; Amoah et al., 2007).
PLs harbouring purified PfMDR1 were prepared using
methods described earlier for PfCRT (Lekostaj et al., 2008b).
In brief, total protein was determined using the amido black
assay, crude yeast membranes (CMs) were solubilized with
dodecyl maltoside (DM), and protein purified by nickel che-
lation chromatography. CMs were diluted to 2 mg ml-1 in a
Tris-based wash buffer [50 mM Tris-HCl, 250 mM sucrose,
20% (v/v) glycerol and 1 mM MgCl2 (pH 7.5), supplemented
with 3 M NaCl] and centrifuged at 100 000 g for 1 h. The
washed pellet was resuspended at 2 mg ml-1 in solubilization
buffer (wash buffer supplemented with 500 mM NaCl and 1%
DM). The sample was rotated for 30 min, and centrifuged for
1 h at 100 000 g. The detergent extract was then applied to a
His GraviTrap column (GE Healthcare) and allowed to flow
through via gravity. The column was washed with several bed
volumes of 20 mM imidazole to remove non-specifically
bound proteins, and PfMDR1 was eluted with 500 mM imida-
zole, into polar Escherichia coli lipid suspension at a final
concentration of 1.2% lipid. Protein–lipid mixtures were
rotated gently for 30 min and then dialysed against 50 mM
Tris-HCl, 250 mM sucrose and 1 mM EDTA (pH 7.5) for 20 h.
Purified PfMDR1 PLs were centrifuged for 1 h at 100 000 g,
pellets were resuspended in fresh dialysis buffer, and snap-
frozen in dry ice-ethanol. Purified protein levels were rede-
termined using the amido black assay.
Drug competition with AzBCQ photolabelling
The synthesis of AzBCQ and optimization of photolabelling
conditions within a 96-well plate format has been described in
detail previously (Lekostaj et al., 2008b). Experiments with
PfMDR1 PLs were carried out with minor modifications
(Pleeter et al., 2010). Briefly, a fixed amount (4.0 mg per well)
of purified PL protein was diluted in a 50 mM Mes-Tris buffer
at pH 5.2. The PL-buffer solution was aliquoted into wells of
a 96-well UV transparent plate. Either buffer or competing
drug solution was added to each respective well, followed by
the addition of 0.5 mM AzBCQ. The plate was shaken at 650
r.p.m. for 30 s and then incubated for 10 min at 37°C in a
water bath. The plate was then exposed to UV radiation
(254 nm maximum) at 1 cm distance for 10 min. The reaction
was quenched with the addition of an equal volume of
Laemmli sample buffer. The samples were again incubated
for 10 min at 37°C, divided in half, and loaded onto two
parallel 7.5% bis-acrylamide Tris-HCl gels. For AzBCQ pho-
tolabelling detection, blots were blocked in 10% milk and
probed with streptavidin-HRP (1:400). For quantification of
PfMDR1 protein present, C-terminal hexaHis tags were
probed with the Qiagen PentaHis detection kit according to
the manufacturer’s instructions (Lekostaj et al., 2008b).
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